Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.52 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16999330 | 1.00 | USP30 (0.59) | USP30SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16999362 | 0.87 | KDM4E (0.53) | USP30SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16999319 | 0.87 | PABPC1 (0.66) | USP30SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16994018 | 0.87 | KDM4E (0.53) | USP30SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16999703 | 0.87 | KDM4E (0.53) | USP30SMN1; SMN2ALDH1A1KDM4EPABPC1 | |
| SCHEMBL16994059 | 0.87 | KDM4E (0.53) | USP30SMN1; SMN2ALDH1A1KDM4EPABPC1 | |
| SCHEMBL16993880 | 0.87 | HSPA5 (0.64) | USP30SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16999340 | 0.87 | HSPA5 (0.64) | USP30SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16993979 | 0.87 | PABPC1 (0.66) | USP30SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16999832 | 0.85 | KMT2A (0.50) | USP30KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102193-B1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | UNIV RUTGERS (US) | 2023-01-11 | — | — | EP | disclosed |
| US-9919998-B2 | Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3102193-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | Rutgers, The State University of New Jersey (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160347708-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2016-12-01 | — | — | US | disclosed |
| WO-2015120320-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347708-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | TYR, NAT1, AANAT | USP30 2618/4885SMN1; SMN2 2997/4885ALDH1A1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.